SARS-CoV-2 NSP7 (26-40)
The SARS-CoV-2 non-structural protein 7 (NSP7) sequence SKLWAQCVQLHNDIL (26-40) has been identified as an epitope for anti-viral targeting.
Catalogue number crb1001763 Molecular Weight 1766.9 Sequence (one letter code)
Sequence (three letter code)
Purity >95% Storage -20°C References
Le Bert et al., (2020). SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature, 584: 457. doi: 10.1038/s41586-020-2550-z.
Safavi et al., (2020). Exploring the out of sight antigens of SARS-CoV-2 to design a candidate multi-epitope vaccine by utilizing immunoinformatics approaches. Vaccine, 38(48): 7612. doi: 10.1016/j.vaccine.2020.10.016.
Manufactured in: United Kingdom
SARS-CoV-2 NSP7 is part of the RNA-dependent RNA polymerase heterotetramer for mediating coronavirus RNA synthesis. NSP7 and NSP8 form a channel to confer processivity on RNA polymerase. NSP7 aids in stabilising NSP12 regions involved in RNA binding and is essential for a highly active NSP12 polymerase complex. These factors make NSP7 a good target for developing new antiviral drugs. In addition, the identification of epitopes within the NSP7 sequence can help design more effective SARS-CoV-2 vaccines.
Models have predicted epitopes exhibiting antigenicity, stability and interactions with MHC class-I and class-II molecules. NSP7 (26-40) is an epitope candidate with various HLA restrictions. This epitope can be used to better vaccine design for more durable CD4+ and CD8+ T cell responses for long-lasting immunity.